Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure.
Tarun W Dasari, Praloy Chakraborty, Peter Mukli...
https://pubmed.ncbi.nlm.nih.gov/37943335/Actively Recruiting
Led by University of Oklahoma · Updated on 2025-05-28
100
Participants Needed
1
Research Sites
N/A
Total Duration
Acute Decompensated Heart Failure ADHF is a serious condition linked to increased inflammation and poor health outcomes. This research aims to study whether low-level tragus nerve stimulation LLTS, a non-invasive method to influence nerve activity, can reduce inflammation and improve heart function in patients with ADHF. The study evaluates changes in inflammatory markers, heart rate variability, kidney function, and breathing difficulty during hospitalization. Participants will be randomly assigned to receive either active LLTS or a sham inactive stimulation for 2 hours each day. The active treatment uses a device with electrodes attached to the ear to provide neuromodulation. Blood samples will be taken shortly after hospital admission and again at discharge to measure inflammatory and heart failure markers. Daily ECG recordings will assess heart rate variability, and patients will rate their breathing difficulty using a visual scale. During the hospital stay, participants will undergo regular blood tests, ECGs, and symptom assessments to monitor changes in inflammation, heart and kidney function, and breathing. The main outcomes include changes in cytokine levels, heart failure biomarkers, and heart rate variability over approximately 3 to 6 days. This study seeks to provide new evidence on the effects of LLTS in improving inflammation and symptoms in ADHF patients.
CONDITIONS
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
T
Tarun Dasari, MD,MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Oklahoma
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | LLTS (investigational) | No Intervention (control) | Standard ADHF Care (context) |
|---|---|---|---|
| What it is | A noninvasive device delivering low‑level electrical stimulation to the tragus of the ear (LLTS) applied 2 hours daily | Participants receive no intervention as the control condition | Guideline‑recommended treatment includes prompt decongestion with diuretics and initiating guideline‑directed medical therapy for patients with acute decompensated heart failure |
| Role in trial | Investigational device arm receiving LLTS | Randomized control arm with no intervention | Usual inpatient management as per clinical practice guidelines |
| Primary use | To modulate autonomic or inflammatory responses in acute decompensated heart failure | Serves as control comparator to evaluate LLTS effects | Manage fluid overload and stabilize patient using evidence‑based medical therapy |
| Administration or procedure | Applied via ear electrodes for 2 hours each day using a transcutaneous electrical nerve stimulation device | No device or procedure administered | Intravenous diuretics and initiation of medical therapy as per protocols |
| Evidence status | Early clinical data suggest LLTS may reduce inflammation and oxidative stress, but efficacy in improving clinical outcomes remains under investigation | Serves as baseline comparator; no efficacy data by itself | Standard decongestive and guideline‑directed therapies have established benefit in acute HF management |
| Important risks | Unknown safety profile in acute decompensated heart failure beyond small studies | No intervention implies no added procedural risk | Known risks include electrolyte disturbances or kidney impairment from diuretics plus other drug side effects |
| Important limitations | Effectiveness on clinical outcomes such as symptom improvement or hospital stay is not yet established | Provides only baseline comparison; no therapeutic value on its own | Guideline therapies require clinical monitoring and may not be feasible in all care settings |
| Patient impact | Potential to reduce inflammation may translate to faster recovery, but patient‑level benefits remain investigational | Allows assessment of new treatment effect but itself offers no direct benefit | Clinical outcomes are supported by evidence when treatment is delivered promptly and safely |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Average 3 to 6 days
Participants receive either active low-level transcutaneous tragus stimulation or sham stimulation for 2 hours daily to evaluate effects on inflammation and heart rate variability during hospitalization for acute decompensated heart failure.
Daily treatment sessions during hospitalization
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tarun W Dasari, Praloy Chakraborty, Peter Mukli...
https://pubmed.ncbi.nlm.nih.gov/37943335/Tarun Dasari, Praloy Chakraborty, Peter Mukli...
https://pubmed.ncbi.nlm.nih.gov/37790298/University of Oklahoma
Lead Sponsor